Is daytime insulin more physiologic and less atherogenic than bedtime insulin?

Medical Hypotheses

Volumn 68, Issue 6, 2007, Pages 1228-1232

  Kanat, Mustafa ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIDIABETIC AGENT; GLUCAGON; GLUCOSE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; COMPARATIVE STUDY; DRUG CLEARANCE; DRUG HALF LIFE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IATROGENIC DISEASE; INHIBITION KINETICS; INSULIN RELEASE; INSULIN TREATMENT; LIVER CLEARANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PORTAL VEIN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK FACTOR; STANDARD;

ATHEROSCLEROSIS; BLOOD GLUCOSE; CHRONOTHERAPY; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MODELS, BIOLOGICAL;

EID: 34047097739     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.037     Document Type: Article

References (46)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
3. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
6. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
7. Gastaldelli A., Ferrannini E., Miyazaki Y., Matsuda M., and DeFronzo R.A. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47 (2004) 31-39
8. Eldor R., Stern E., Milicevic Z., and Raz I. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pr 68S1 (2005) S30-S35
9. ADA. Standards of medical care in diabetes. Diabetes Care 28 Supp.1 (2005) S4-S36
10. Nathan D.M. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347 (2002) 1347-1349
11. Lebovitz H.E. Oral therapies for diabetic hyperglycemia. Endocrin Metab Clin North Am 30 (2001) 909-933
12. Davis T., and Edelman S.V. Insulin therapy in type 2 diabetes. Med Clin N Am 88 (2004) 865-895
13. Yki-Jarvinen H., Kauppila M., Kujansuu E., Lahti J., Marjanen T., Niskanen L., et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327 (1992) 1426
14. Riddle M.C. Evening insulin strategy. Diabetes Care 13 (1990) 676
15. Wulffele M.G., Kooy K., Lehert P., Bets D., Ogterop J.C., Van Der Burg B.B., et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25 12 (2002) 2133-2140
16. Buse J.B., Gumbiner B., Mathias N.P., Nelson D.M., Faja B.W., Whitcomb R.W., and Troglitazone Insulin Study Group. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 21 9 (1998) 1455-1461
17. Wolffenbuttel B.H., Sels J.P., Rondas-Colbers G.J., Menheere P.P., and Nieuwenhuijzen Kruseman A.C. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 19 (1996) 1326-1332
18. Yki-Jarvinen H., Ryysy L., Kauppila M., Kujansuu E., Lahti J., Marjanen T., et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82 (1997) 4037-4043
19. Grundy S.M., Benjamin I.J., Burke G.L., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Asscociation. Circulation 100 (1999) 1134-1146
20. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
21. Hu F.B., Stampfer M.J., Solomon C.G., et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 161 (2001) 1717-1723
22. Calles-Escandon J., and Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 22 (2001) 36-52
23. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
24. Carr M.E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 15 (2001) 44-54
25. Nordt T.K., and Bode C. Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches. Semin Thromb Hemost 26 (2000) 495-501
26. Davi G., Catalano I., Averna M., Notarbartolo A., Strano A., Ciabattoni G., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322 (1990) 1769-1774
27. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46 (1995) 223-234
28. Stevens M.J., Raffel D.M., Allman K.C., Dayanikli F., Ficaro E., Sandford T., et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98 (1998) 961-968
29. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
30. Pyorala M., Miettinen H., Laakso M., and Pyorala K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 23 (2000) 1097-1102
31. Fonseca V., Desouza C., Asnani S., et al. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25 (2004) 153-175
32. Haffner S.M., D'Agostino Jr. R., Mykkanen L., Tracy R., Howard B., Rewers M., et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the insulin resistance atherosclerosis study. Diabetes Care 22 (1999) 562-568
33. Spoelstra-de M., Brouwer C.B., Stehouwer C.D., and Smulders Y.M. Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care 24 (2001) 2097-2101
34. Kark J.D., Selhub J., Bostom A., Adler B., and Rosenberg I.H. Plasma homocysteine and all-cause mortality in diabetes. Lancet 353 (1999) 1936-1937
35. Bonora E., and Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 44 (2001) 2107-2114
36. Saltiel A.R., and Kahn C.R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
37. Zeng G., Nystrom F.H., Ravichandran L.V., Cong L.N., Kirby M., Mostowski H., et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101 (2000) 1539-1545
38. Hsueh W.A., and Law R. Insulin signaling in the arterial wall. Am J Cardiol 84 (1999) 21J-24J
39. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin N Am 88 (2004) 787-835
40. Krook A., Bjornholm M., Galuska D., Jiang X.J., Fahlman R., Myers M.G., et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49 (2000) 284-292
41. Dandona P., Chaudhuri A., and Aljada A. Endothelial dysfunction and hypertension in diabetes mellitus. Med Clin North Am 88 (2004) 911-931
42. Ding Y., Vaziri N.D., Coulson R., Kamanna V.S., and Roh D.D. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab 279 (2000) E11-E17
43. Fener E.P., and King G.L. Vascular dysfunction in diabetes mellitus. Lancet 350 (1997) 9-13
44. Baron A.D., Schaeffer L., Shragg P., and Kolterman O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36 (1987) 274-283
45. Duckworth W.C., Bennet R.G., and Hamel F.G. Insulin degradation: progress and potential. Endocr Rev 19 5 (1998) 608-624
46. Duckworth W.C., Saudek C.D., Henry R.R., and Veterans Affairs Study Group. Perspectives in diabetes: why intraperitoneal delivery of insulin with implantable pumps in NIDDM?. Diabetes 41 (1992) 657